NCT07848659PHASE1RecruitingAccepts Healthy Volunteers

Study of Single Doses of HBS-104 in Acutely Sleep-deprived Healthy Participants

Harmony Biosciences Management, Inc.

Start Date

8/28/2026

Completion Date

2/18/2027

Summary

This is a study to evaluate the pharmacodynamic effects, safety, tolerability, and pharmacokinetics of HBS-104 in acutely sleep-deprived healthy adult participants.

Detailed Description

Single oral doses of HBS-104 (low, medium or high doses) or matching placebo will be administered in 4 double-blind treatment periods in a crossover design. Each treatment period is 4 days in duration (Days -1 to 3) separated by a 7 to 12 day washout interval.

Eligibility Criteria

Age Range: 18 years to 55 years

Inclusion Criteria: * Provide written informed consent before any study-related procedures are performed. * Be healthy as determined by assessments at the Screening Visit. Exclusion Criteria: * Female with a positive pregnancy test at Screening Visit or upon check-in for Period 1. * Is currently breastfeeding or planning to breastfeed over the course of the study. Lactating women must agree not to breastfeed for the duration of the study and for 7 days after their final dose of study drug. Note: Additional inclusion/exclusion criteria may apply, per protocol

Interventions

DRUG

HBS-104

DRUG

Placebo

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Sleep Deprivation

Locations

Sponsor Clinical Site - New Jersey

Eatontown, New Jersey 07724

United States